40-60 mg/day PO initially (in single daily dose or divided q12hr for 1 week if patient needs to adjust to therapy) Titrate dose in increments of 30 mg/day over 1 week as tolerated Target dosage: 60 mg/day PO (in single daily dose or divided q12hr); not to exceed 120 mg/day (safety of dosages Treatment of chronic musculoskeletal pain, including discomfort from osteoarthritis and chronic lower back pain 30 mg/day PO initially for 1 week to allow for therapy adjustment Target dosage: 60 mg/day PO; not to exceed 60 mg/day Dosages ≥60 mg/day have not been shown to offer additional benefits Major depressive disorder and generalized anxiety disorder: Acute episodes often necessitate several months of sustained therapy Diabetic peripheral neuropathic pain: Efficacy for 12 weeks has not been studied; if diabetes is complicated by renal disease, consider lower starting dosage with gradual increase to effective dosage Fibromyalgia: Efficacy for ≥12 weeks has not been studied; continue treatment on basis of individual patient response Chronic musculoskeletal pain: Efficacy for ≥13 weeks has not been studied Uncontrolled narrow-angle glaucoma: Use not recommended due to increased risk of mydriasis Constipation (10%) Dizziness (10%) Insomnia (10%) Diarrhea (9-10%) Anorexia (8%) Decreased appetite (7-8%) Abdominal pain (6%) Hyperhidrosis (6%) Increased sweating (6%) Agitation (5%) Nasopharyngitis (5%) Vomiting (3-5%) Male sexual dysfunction (2-5%) Abdominal pain (4%) Decreased libido (4%) Musculoskeletal pain (4%) Upper respiratory tract infection (URTI) (4%) Abnormal orgasm (3%) Agitation (3%) Anxiety (3%) Blurred vision (3%) Cough (3%) Influenza (3%) Muscle spasms (3%) Tremor (3%) Abnormal dreams (2%) Dyspepsia (2%) Hot flushes (2%) Nausea (2%) Oropharyngeal pain (2%) Palpitations (2%) Paresthesia (2%) Weight loss (2%) Yawning (2%) Dysuria ( General: Anaphylactic reaction, angioneurotic edema, hypersensitivity Cardiovascular: Hypertensive crisis, supraventricular arrhythmia, myocardial infarction, tachycardia, Takotsubo cardiomyopathy Endocrine: Galactorrhea, gynecologic bleeding, hyperglycemia, hyperprolactinemia Neurologic: Restless legs syndrome, seizures upon treatment discontinuance, extrapyramidal disorders Ophthalmic: Glaucoma Otic: Tinnitus (upon treatment discontinuance) Psychiatric: Aggression and anger (particularly early in treatment or after treatment discontinuance), hallucinations Musculoskeletal: Trismus, muscle spasm Skin: Serious skin reactions (eg, erythema multiforme and Stevens-Johnson syndrome) necessitating drug discontinuance or hospitalization, urticaria, rash Gastrointestinal: Colitis (microscopic or unspecified),cutaneous vasculitis (sometimes associated with systemic involvement), acute pancreatitis Antidepressants increased the risk of suicidal thoughts and behavior in children, adolescents, and young adults in short-term studies These studies did not show an increase in the risk of suicidal thoughts and behavior with antidepressant use in patients 24 yr There was a reduction in risk with antidepressant use in patients ≥65 yr In patients of all ages who are started on antidepressant therapy, monitor closely for worsening, and for emergence of suicidal thoughts and behaviors Advise families and caregivers of the need for close observation and communication with the prescriber CYP1A2 inhibitors or thioridazine should not be coadministered Use caution in severe renal impairment, ESRD Heavy alcohol use Suicidality; monitor for clinical worsening and suicide risk, especially in children, adolescents and young adults (18-24 years) during early phases of treatment and alterations in dosage Serotonin syndrome or neuroleptic malignant syndrome-like reactions may occur; discontinue and initiate supportive therapy; closely monitor patients concomitantly receiving triptans, antipsychotics and serotonin precursors Neonates exposed to serotonin-noreponephrine reuptake inhibitors (SNRIs) or selective serotonin reuptake inhibitors (SSRIs) late in 3rd trimester of pregnancy have developed complications necessitating prolonged hospitalization, respiratory support, and tube feeding Screen patients for bipolar disorder; risk of mixed/manic episodes is increased in patients treated with antidepressants May cause activation of mania or hypomania Increased risk of hepatotoxicity, sometimes fatal; monitor for abdominal pain, hepatomegaly, elevations in hepatic transaminases exceeding 20 times upper limit of normal; jaundice; cholestatic jaundice with minimal elevations of hepatic transaminases have also been reported; use not recommended in patients with substantial alcohol use or chronic liver disease SSRIs and SNRIs may impair platelet aggregation and increase the risk of bleeding events, ranging from ecchymoses, hematomas, epistaxis, petechiae, and GI hemorrhage to life-threatening hemorrhage; concomitant use of aspirin, NSAIDs, warfarin, other anticoagulants, or other drugs known to affect platelet function may add to this risk Severe skin reactions (eg, erythema multiforme and Stevens-Johnson syndrome); discontinue at first appearance of blisters, peeling rash, mucosal erosions, or any other sign of hypersensitivity if no other etiology can be identified Orthostatic hypotension and syncope, especially during week 1 of therapy; monitor patients taking drugs that increase risk of orthostatic hypotension; consider dose reduction or discontinue therapy in patients who experience symptomatic orthostatic hypotension, falls and/or syncope Hyponatremia due to syndrome of inappropriate antidiuretic hormone (SIADH); cases of serum sodium Exact mechanism of action unknown; inhibits reuptake of serotonin and norepinephrine; weakly inhibits reuptake of dopamine; has no MAOI activity; has no significant activity for histaminergic H1 receptor or alpha2-adrenergic receptor The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information. For questions about expired web site content, you may email clevelandclinicmeded [at] ccf [dot] org. For questions concerning RSS credit or the my CME system, please write to mycme [at] ccf [dot] org. Buy propranolol 80 mg Where can i buy kamagra in amsterdam NCI Dictionary of Cancer Terms. It is also being studied in the treatment of peripheral neuropathy caused by certain anticancer drugs. Cymbalta increases the amount of certain chemicals in the brain that help relieve depression and pain. It is a type of serotonin and norepinephrine reuptake inhibitor. Also called duloxetine and duloxetine hydrochloride. Return to Pharmacotherapy Update Index. Duloxetine Cymbalta®; Eli Lilly and Co. is classified as a selective serotonin and norepinephrine reuptake inhibitor SSNRI. Medscape - Generalized anxiety disorder, major depressive disorder, fibromyalgia-specific dosing for Cymbalta duloxetine, frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information. Duloxetine hydrochloride is used in MS to treat depression and neuropathic pain. It belongs to a group of medications known as selective serotonin and norepinephrine reuptake inhibitors (SSNRI). A drug used to treat depression and peripheral neuropathy (pain, numbness, tingling, burning, or weakness in hands or feet) that can occur with diabetes. It is also being studied in the treatment of peripheral neuropathy caused by certain anticancer drugs. Duloxetine increases the amount of certain chemicals in the brain that help relieve depression and pain. A type of reuptake inhibitor of serotonin and norepinephrine. Duloxetine definition Duloxetine Cymbalta, Antidepressant, Side Effects, Dosing, Uses, Pharmacotherapy Update Duloxetine Cymbalta® Viagra chemical formulaCan you buy clomid over the counter in australiaHow to purchase prednisoneOrder doxycycline overnightBuy liquid viagra Mean plasma clearance is approximately 101 L/hr, with a mean volume of distribution of about 1640 L, meaning that duloxetine is distributed throughout the. Duloxetine Dual-action antidepressant MDedge Psychiatry. Cymbalta duloxetine dosing, indications, interactions, adverse.. Cymbalta Oral Uses, Side Effects, Interactions, Pictures, Warnings.. Duloxetine is a molecule commercialized under the name Cymbalta®. It is a drug that is prescribed primarily for depression, though also occasionally used as an anxiolytic to reduce stress, or to calm pains of the nervous system, particularly in persons with diabetes. This medication is for adult use only, and must be prescribed by a doctor. Cymbalta Brand name for duloxetine hydrochloride, a drug approved by the FDA to treat major depresssion in adults and to manage the pain associated with diabetic peripheral neuropathy, nerve damage in diabetes. The drug acts as a serotonin and norepinephrine reuptake inhibitor, increasing the levels of serotonin and norepinephrine, two neurotransmitters, or chemical messengers, believed to be important in regulating a person's emotions as well as reducing the sensitivity to pain. A drug of the SNRI class, C 18 H 19 NOS, used in its hydrochloride form to treat depression, anxiety, fibromyalgia, and diabetic neuropathy.